NMDA受体拮抗剂对阿片类药物耐受和依赖的阻断作用

本文综述阻断ＮＭＤＡ受体离子通道复合药物对阿惩耐受和成瘾发生的影响。行为药理学研究显示,非竞争性ＮＭＤＡ受体拮抗剂、竞争性ＮＭＤＡ受体拮抗剂和甘氨酸受占拮抗剂能抑制阿片耐受和戒断反应,其药理学特性明显不同于其他类型抗阿片耐受和成瘾的药物,阐述了ＮＭＤＡ受体拮抗剂治疗阿片类芗耐受和领事的系列化机制。并指出ＮＭＤＡ受体拮抗剂具有神经毒性。     

NMDA受体与中枢神经系统发育

中枢神经系统兴奋性氨基酸离子型受体－ＮＭＤＡ受体,是由ＮＭＤＡＲ１和ＮＭＤＡＲ２两个亚单位共同构成的受体通道复合体。ＮＭＤＡ受本激活后可引起神经元细胞对Ｎａ＾＋,Ｋ＾＋和Ｃａ＾２＋通透性增强,产生兴奋性突触后电位,在中枢神经发育的过程中,ＮＭＤＡ受体通过不同亚型的选择性表达,改变自身的结构和功能,进而影响ＮＭＤＡ受体介导的Ｃａ＾２＋内流,调节神经元内Ｃａ＾２＋依赖的第二信使系统,最终实现对中枢神经     

谷氨酸NMDA受体与惊厥

本文介绍了近几年对谷氨酸ＮＭＤＡ受体的研究进展,并就中枢神经系统中,ＮＭＤＡ受体发育,分布特点及其受体激动剂与拮挤在惊厥中的作用等方面探讨了该受体与惊厥产生,发展和扩散的关系,同时也概述了惊厥发生机制中ＮＭＤＡ受体可能起的作用。     

NMDA受体与中枢神经系统的发育

离子型谷氨酸受体分为NMDA型和非NMDA型两类,其中NMDA型受体与中枢神经系统发育关系密切。本文综述了NMDA受体的分子特性及NMDA受体五种亚单位NR1、NR2A、NR2B、NR2C和NR2D在动物出生后脑内的时空表达;NMDA受体亚单位在发育中的作用以及NMDA受体活性的胞内调节机制。     

NMDA和非NMDA受体拮抗剂对伤害性辐射热引起的缩腿反射抑制的比较

我们以前的电生理工作：Ｎ－甲基－Ｄ－门冬氨酸受体主要参与介导皮肤来源的伤害性信息的传入,而非ＮＭＤＡ受体主要参与介导肌肉来源的伤害性信息的传入。为进一步证实这一发现,应用鞘内注射的方法,观察ＮＭＤＡ和非ＮＭＤＡ受体拮抗剂对大鼠伤害性辐射热刺激所引起的缩腿反射潜伏期的影响。     

NMDA受体的结构及其生理作用

N-甲基-D-天冬氨酸（NMDA）受体是离子型兴奋性谷氨酸受体的一种亚型,生物体内已发现了3种NMDA受体亚基,且通过选择性剪接至少存在7种亚型,形成具有功能的多结合位点的大分子复合物。NMDA受体在中枢神经系统的突触传递、突触可塑性、学习记忆等生理过程中发挥着重要作用,且NMDA受体的异常会导致-些精神疾病及认知功能的障碍。     

离子型NMDA受体在缺氧耐受中的作用

离子型ＮＭＤＡ受体在缺氧耐受中的作用谢静晖吕国蔚（首都医科大学神经生物系,北京１０００５４）机体缺氧时的脑损伤与脑内兴奋性氨基酸（ＥＡＡｓ）增多及其受体激活引起的兴奋毒性作用有关;而重复缺氧可形成预适应而显著提高小鼠对缺氧的耐受性。本研究观察ＥＡＡｓ...     

NMDA受体与Ⅰ组代谢型谷氨酸受体的相互作用

谷氨酸是哺乳动物中枢神经系统重要兴奋性神经递质,参与学习、记忆、药物依赖成瘾及神经系统退行性疾病等多种病理生理过程。谷氨酸通过激活离子型（iGluRs）和代谢型谷氨酸受体（mGluRs）发挥作用。业已有研究提示iGluRs和mGluRs之间存在相互作用,但具体机制尚待阐明。本文从蛋白分子结构、突触可塑性、相互作用可能涉及的信号分子和通路等方面综述了NMDAR与Ⅰ组mGluRs之间的相互作用,旨在为深入研究谷氨酸受体之间的相互作用提供线索。     

NMDA受体与鸣禽鸣唱学习记忆

N-2-甲基-D-天冬氨酸(N-methy-2-D-asparticacid,NMDA)受体,是一种分布在突触后膜上的离子通道蛋白,受突触电压和神经递质(如谷氨酸、甘氨酸、NMDA等)的双重调控,是参与学习与记忆过程的关键物质.鸣禽的鸣唱是一种习得性行为,是在特定的学习敏感期依赖听觉经验完成的.对近年来鸣禽NMDA受体与鸣禽鸣唱学习的研究进展进行了综述.     

大脑皮层神经元NMDA受体的单通道特性

本文用膜片箝技术对机械分离培养的大鼠大脑皮层神经元胞体上的ＮＭＤＡ受体的单通道特性进行了研究,实验用细胞贴附和内面向外两种形式记录单离子通道的活动。电极液内含有ＮＭＤＡ或Ｌ－门冬氨酸时,在皮层神经元上常见电导为３５ｐＳ的离子通道。通道对Ｎａ＋,Ｋ＋非选择性通透,对Ｃｌ－不通透,其平均开放时间和开放概率随超极化程度增大而降低。开放、关闭时间及ｂｕｒｓｔ时程的分布直方图均需双指数拟合。Ｍｇ２＋以电压和浓度依赖性的方式减小通道开放时间,ＡＰＶ能阻断通道活动,温度降低使通道开放时间延长及电流幅度减小。本文结果表明大脑皮层神经元上ＮＭＤＡ受体通道活动自身具有电压依赖性,因此提示ＮＭＤＡ受体通道的正常功能活动可能依赖于某些细胞内调控过程的存在。     

Competitive NMDA receptor antagonists raise electrically kindled generalized seizure thresholds

A sensitive method of estimation of generalized seizure thresholds (GSTs) was used to estimate the relative anticonvulsant potencies of four competitive NMDA antagonists against fully amygdala-kindled seizures. All of the antagonists tested showed potent, dose-dependent anticonvulsant activity following focal administration at doses causing no, or only minimal, overt behavioural abnormalities. These doses were similar to those which have previously been shown to inhibit the development of the kindling process i.e. which show antiepileptogenic activity. Two novel, competitive NMDA antagonists, CGP 37849 and CGP 39551, both unsaturated analogues of the NMDA antagonist AP5, showed by far the greatest anticonvulsant potencies (211-fold and 33-fold greater activity than the parent molecule, respectively). Recent reports of oral anticonvulsant activity of these two compounds in both rodent and primate models of epilepsy (12, 13) make them leading candidates for clinical testing as novel antiepileptic agents in man. Previous reports of weak or non-existent anticonvulsant activity of competitive NMDA antagonists in the kindling model of epilepsy most likely result from the use of experimental protocols which are inherently insensitive in detecting drug-induced changes in seizure thresholds.Special issue dedicated to Dr. Morris H. Aprison.     

Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease

Summary In animal models of Parkinson's disease (PD), glutamate antagonists diminish levodopa (LD)-associated motor fluctuations and dyskinesias. We sought to investigate if these preclinical observations can be extended to the human disease, by evaluating the effects of three non-competitive NMDA antagonists (dextrorphan, dextromethorphan and amantadine) on the motor response to LD in patients with advanced PD. In four separate trials, adjuvant therapy with these drugs reduced LD-induced dyskinesias and motor fluctuations. These findings support the view that drugs acting to inhibit glutamatergic transmission at the NMDA receptor can ameliorate LD associated motor response complications.     

Effects of modulators of N-methyl-D-aspartate receptor-mediated neurotransmission on diazepam discrimination in rats

N-methyl-D-aspartate (NMDA) antagonists share a number of pharmacological effects with GABA(A) agonists, including anxiolytic and anticonvulsant effects. This study evaluated the effects of site-selective NMDA antagonists in rats trained to discriminate the benzodiazepine diazepam from vehicle. As expected, diazepam produced robust discriminative stimulus effects and dose-dependently substituted for the training dose. Mixed results were obtained with competitive NMDA antagonists: whereas NPC 17742 partially substituted for diazepam, SDZ EAA 494 did not elicit responding on the diazepam-associated lever. Other site-selective NMDA antagonists, including the open channel blocker phencyclidine, the glycine-site antagonists ACEA 1021 and MDL 102,288, the polyamine-site antagonist arcaine, and the glutamate release inhibitor riluzole, failed to substitute for diazepam. Agonists at nonbenzodiazepine sites of the GABA(A) receptor complex were also tested for comparison purposes. The barbiturate pentobarbital and the neurosteroid Co 2-1068 partially substituted for diazepam. In contrast, the anticonvulsant carbamazepine failed to substitute even at a dose that substantially reduced response rates. These results suggest that substitution of NMDA antagonists for GABA(A) agonists is dependent upon the site at which the NMDA antagonist binds. Further, they suggest that similarities between the stimulus properties of GABA(A) agonists and NMDA antagonists are at least as strong as similarities among agonists acting at different sites on GABA(A) receptors.     

NMDA Receptor antagonists prevent acute ammonia toxicity in mice

We proposed that acute ammonia toxicity is mediated by activation of NMDA receptors. To confirm this hypothesis we have tested whether different NMDA receptor antagonists, acting on different sites of NMDA receptors, prevent death of mice induced by injection of 14 mmol/Kg of ammonium acetate, a dose that induces death of 95% of mice. MK-801, phencyclidine and ketamine, which block the ion channel of NMDA receptors, prevent death of at least 75% of mice. CPP, AP-5, CGS 19755, and CGP 40116, competitive antagonists acting on the binding site for NMDA, also prevent death of at least 75% of mice. Butanol, ethanol and methanol which block NMDA receptors, also prevent death of mice. There is an excellent correlation between the EC₅₀ for preventing ammonia-induced death and the IC₅₀ for inhibiting NMDA-induced currents. Acute ammonia toxicity is not prevented by antagonists of kainate/AMPA receptors, of muscarinic or nicotinic acetylcholine receptors or of GABA receptors. Inhibitors of nitric oxide synthase afford partial protection against ammonia toxicity while inhibitors of calcineurin, of glutamine synthetase or antioxidants did not prevent ammonia-induced death of mice. These results strongly support the idea that acute ammonia toxicity is mediated by activation of NMDA receptors.     

Sex differences in the analgesic effects of ICI 182,780 and Flutamide on ureteral calculosis in rats

To better define the involvement of gonadal hormones in the sex differences observed in experimental visceral pain, we administered antagonists of estrogen receptors (ICI 182,780 [ICI]) or androgen receptors (Flutamide [FLU]) to adult male and female rats suffering from artificial ureteral calculosis. Subjects were divided into groups and treated with one of the substances (ICI, FLU) or sweet almond oil (OIL, vehicle) for 5 days, starting 2 days before surgery. On day 3, animals underwent surgery, with half receiving an artificial calculosis (Stone) and half only a sham procedure. The animals' behavior (number and duration of ureteral crises) and blood hormone levels (estradiol and testosterone) were determined in all groups. In OIL-treated rats the number and duration of crises were higher in females than in males. The administration of ICI or FLU resulted in hormonal effects in males and behavioral effects in females. In males ICI treatment increased estradiol plasma levels and FLU increased testosterone plasma levels; in females ICI and FLU treatments both decreased the number and duration of the ureteral crises. These results, confirming previous findings of higher sensitivity of females than males to urinary tract pain, showed the modulatory effects of estrogen and androgen antagonists on the behavioral responses induced by pain but only in females.     

The role of striatal glutamate receptors in models of Parkinson's disease

Summary The aim of the study was to examine the effect of antagonists of the NMDA receptor on the parkinsonian-like muscle rigidity in rats. Reserpine and haloperidol increased the muscle resistance of the hind foot to passive movements, as well as the reflex electromyographic (EMG) activity in the gastrocnemius and tibialis anterior muscles. MK-801 (0.32-1.28 mg/kg sc), an uncompetitive antagonist of the NMDA receptor, and L-701,324 (5-40 mg/ kg ip), an antagonist of the glycine site, reduced the muscle tone and the reflex EMG activity enhanced by reserpine or haloperidol. AP-5 (2 and 5 ,g/ 0.5 pl), a competitive antagonist of the NMDA receptor, and 5,7-dichlorokynurenic acid (1.0-4.5g/0.5 pl), the glycine site antagonist injected bilaterally into the rostral striatum, inhibited the muscle rigidity induced by haloperidol. In contrast, AP-5, injected alone bilaterally into the intermediate-caudal striatum induced muscle rigidity. The present results suggest that: (1) the inhibitory effect of the NMDA receptor antagonists on the parkinsonian-like muscle rigidity depends, at least partly, on their action on the rostral striatum; (2) the blockade of NMDA receptors in the intermediate-caudal striatum may reduce the beneficial impact of these compounds.     

Glutamate,learning and dementia-selection of evidence

Summary Initial suggestions on the involvement of glutamate in memory came from electrophysiological studies on LTP that is blocked by NMDA-antagonists. Then Morris and colleagues (1986) provided the first evidence that icv infusion of the competitive NMDA antagonist 2-amino-5-phosphonovaleric acid (APV) to rats, inhibits both LTP in vivo and spatial learning in a Morris water maze. This was followed by a great amount of evidence confirming the initial finding in various learning tasks. The present paper is devoted to critical review of the literature focusing on the following problems: which glutamate receptors are involved?, in which tests NMDA antagonists inhibit learning?; which types of memory are affected?; which brain structures are involved?; do NMDA receptor antagonists invariably impair learning?; is the effect of NMDA receptors antagonists on learning specific?; does the stimulation of NMDA receptors result in cognitive enhancement?.     

Disruption of sensitization to methylphenidate by a single administration of MK-801

Blockade of sensitization to methylphenidate by a single injection of MK-801 was investigated using a computerized activity monitoring system. Male Sprague-Dawley rats were housed in test cages and motor activity was recorded continuously for 16 days. After 2 days of baseline recording and a saline injection on day 3, the rats were randomly divided into four experimental groups. All received 2.5 mg/kg of methylphenidate (s.c.) once a day from days 4 to 9, then after five days of no treatment, they were re-challenged with 2.5 mg/kg of methylphenidate on day 15. One group received only methylphenidate, while the other three groups also received a single i.p. injection of MK-801 (0.30 mg/kg) either 24 h (day 3) or 1 h prior to the first of the six methylphenidate injections (day 4), or 1 h prior to the second methylphenidate injection (day 5). A single injection of MK-801 on day 4 (1 h prior to methylphenidate) blocked the development of sensitization to methylphenidate, since a sensitized response could not be elicited six days after cessation of repeated methylphenidate administration (day 15). However, sensitization to methylphenidate still occurred in the groups receiving MK-801 (0.30 mg/kg) on day 5, indicating that the mechanism by which a single injection of MK-801 disrupts sensitization to methylphenidate is sensitive to timing and is not a direct long-term effect. In conclusion, a single injection of MK-801 persistently blocks the development of sensitization to methylphenidate only if it is given with methylphenidate on the first day of the repetitive treatment phase.     

腺苷及其受体阻断剂对蟾蜍离体心脏功能的影响

实验采用离体心脏灌流方法,观察了腺苷,腺苷受体特异性阻断ＤＰＣＰＸ以及非特异性腺苷受体阻断剂茶碱对两栖类动物蟾蜍的离体心脏力和心率的影响。结果显示,腺苷对心脏收缩力和心率有明显的剂量依赖性抑制作用。单纯的ＤＰＣＰＸ或茶碱对心肌收缩力和心率无显著影响,但在含腺苷的灌流液中加入ＤＰＣＰＸ或茶碱后,对腺苷有明显的拮抗效应。